USANA Health Sciences

Usana Health Sciences reported Q2 adjusted EPS of $0.07 on roughly $223 million in sales, missing analyst estimates on both earnings and revenue. The company will record a $29 million goodwill impairment for its Hiya business and now expects a loss of about $11 million for the year versus prior guidance for $20–27 million in profit. Full-year sales guidance was lowered to $910 million (from $925 million–$1 billion); core nutrition shows stabilization but Hiya and Rise remain weak, leaving the stock under near-term pressure. » More on finance.yahoo.com

USANA Health Sciences reported an adjusted loss of $0.07 per share for Q2 on revenues of $223 million, missing estimates by a wide margin. The company took a non-cash impairment charge of $29.1 million, which pushed the GAAP net loss to $21.4 million. The full-year guidance was sharply cut (EPS $0.76 vs. consensus $2.12; revenue forecast $910 million), and declining core customer counts heightened concerns, after which the stock fell about 26% and hit a 52-week low. » More on de.investing.com

USANA reported revenue of $250 million and earnings per share of $0.61 for the first quarter of 2026, with both metrics comfortably beating expectations. EPS was 52.5% above the forecast and the stock rose 2.6% to $19.26 after the announcement. Growth was driven by strong business activity in China, new products, and progress in the transformation to an omni-channel platform. The company reaffirmed its full-year revenue guidance of $925 million to $1 billion and expects omni-channel sales to make up more than 20% of net sales. » More on de.investing.com